Recent data underscores the need for improved primary care detection of heart failure with preserved ejection fraction.

What exactly happens in the hearts of patients with heart failure with preserved ejection fraction (HFpEF)—and how can this ...

"Atrial fibrillation and heart failure are growing epidemics, and both beget each other." ---- Jonathan Hsu, MD, MAS, University of California San Diego “Atrial fibrillation and heart failure are ...

Sotatercept significantly reduces pulmonary vascular resistance in patients with CpcPH–HFpEF compared with placebo, according to a trial.

Patients with heart failure with preserved ejection fraction (HFpEF) represent approximately 50% of all HF cases. Whereas several proven medical therapies are available for HF with reduced ejection ...

Data Trends provide quick, visually memorable data-driven information and insights that are useful in clinical practice.

In a new research report, a team of scientists led by Johns Hopkins Medicine say people with severe obesity and a common type ...

Cytokinetics, Incorporated has announced the enrollment opening for AMBER-HFpEF, a Phase 2 randomized, placebo-controlled clinical trial evaluating the safety and tolerability of CK-586 in patients ...

Please provide your email address to receive an email when new articles are posted on . Compared with just a few years ago, medical treatment options for HF with preserved ejection fraction have ...

HFpEF in hypertrophic cardiomyopathy predicts adverse outcomes. Discover how machine learning improves risk assessment.

The EMPEROR-Preserved trial of empagliflozin (Jardiance; Boehringer Ingelheim/Eli Lilly) met its primary endpoint, according to top-line results released today, meaning a therapy with specific ...